Login Form
Drugs
The following nanomedicines have been co-developed by the UBC NanoMedicines Research Group and industry partners:
| Drug | Trade Name | Indication | Status (2020) | Company |
| LNP Amphotericin | Abelcet | Fungal infections | Approved US, Europe - 1995 | Enzon/Canadian Liposome Company |
| LNP Doxorubicin | Myocet | Metastatic breast cancer | Approved Europe, Canada - 2000 | Cephalon/Canadian Liposome Company |
| LNP Vincristine | Marqibo | Acute lymphoblastic leukemia | Approved US - 2012 | Spectrum Pharmaceuticals/Inex Pharmaceuticals |
| LNP siRNA TTR | Onpattro (Patisiran) | Transthyretin-induced amyloidosis | Approved US, Europe - 2018 | Alnylam Pharmaceuticals/Acuitas Therapeutics |
| LNP mRNA SARS Cov 2 | Comirnaty | COVID-19 mRNA vaccine | Approved US, Europe - 2021 | Pfizer/BioNTech/Acuitas Therapeutics |
